Karolin Wagner

Ms. Karolin Wagner

Technical University of Munich
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Cell Reports
Verified
Journal Article
Open access
KWKarolin Wagner
Karolin Wagner
LMLaura M. Mateyka
Laura M. Mateyka
SJSebastian Jarosch
Sebastian Jarosch
VGVincent Grass
Vincent Grass
SWSimone Weber
Simone Weber
DBDirk H Busch
Dirk H Busch
T cell immunity is crucial for control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and has been studied widely on a quantitative level. However, the quality of responses, in particular of CD8+ T cells, has only been investigated marginally so far. Here, we isolate T cell receptor (TCR) repertoires specific for immunodominant SARS-CoV-2 epitopes restricted to common human Leukocyte antigen (HLA) class I molecules in convalescent individuals. SARS-CoV-2-specific CD8+ T cells are detected up to 12 months after infection. TCR repertoires are diverse, with heterogeneous functional avidity and cytotoxicity toward virus-infected cells, as demonstrated for TCR-engineered T cells. High TCR functionality correlates with gene signatures that, remarkably, could be retrieved for each epitope:HLA combination analyzed. Overall, our data demonstrate that polyclonal and highly functional CD8+ TCRs—classic features of protective immunity—are recruited upon mild SARS-CoV-2 infection, providing tools to assess the quality of and potentially restore functional CD8+ T cell immunity.

26 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DFDavid S. Fischer
David S. Fischer
MAMeshal Ansari
Meshal Ansari
KWKarolin Wagner
Karolin Wagner
SJSebastian Jarosch
Sebastian Jarosch
YHYiqi Huang
Yiqi Huang
KSKilian Schober
Kilian Schober
The in vivo phenotypic profile of T cells reactive to severe acute respiratory syndrome (SARS)-CoV-2 antigens remains poorly understood. Conventional methods to detect antigen-reactive T cells require in vitro antigenic re-stimulation or highly individualized peptide-human leukocyte antigen (pHLA) multimers. Here, we use single-cell RNA sequencing to identify and profile SARS-CoV-2-reactive T cells from Coronavirus Disease 2019 (COVID-19) patients. To do so, we induce transcriptional shifts by antigenic stimulation in vitro and take advantage of natural T cell receptor (TCR) sequences of clonally expanded T cells as barcodes for ‘reverse phenotyping’. This allows identification of SARS-CoV-2-reactive TCRs and reveals phenotypic effects introduced by antigen-specific stimulation. We characterize transcriptional signatures of currently and previously activated SARS-CoV-2-reactive T cells, and show correspondence with phenotypes of T cells from the respiratory tract of patients with severe disease in the presence or absence of virus in independent cohorts. Reverse phenotyping is a powerful tool to provide an integrated insight into cellular states of SARS-CoV-2-reactive T cells across tissues and activation states.

12 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSophia E. Schambeck
Sophia E. Schambeck
CCClaudia S. Crowell
Claudia S. Crowell
KWKarolin Wagner
Karolin Wagner
Elvira D'IppolitoElvira D'Ippolito
Elvira D'Ippolito
TBTeresa Burrell
Teresa Burrell
HBHenriette Beyer
Henriette Beyer
Deficiencies in smell and taste are common symptoms of COVID-19. Quantitative losses are well surveyed. This study focuses on qualitative changes such as phantosmia (hallucination of smell), parosmia (alteration of smell), and dysgeusia (alteration of taste) and possible connections with the adaptive immune system. Subjective experience of deficiency in taste and smell was assessed by two different questionnaires after a median of 100 and 244 days after first positive RT-PCR test. SARS-CoV-2-specific antibody levels were measured with the iFlash-SARS-CoV-2 assay. After 100 days a psychophysical screening test for olfactory and gustatory dysfunction was administered. 30 of 44 (68.2%) participants reported a chemosensory dysfunction (14 quantitative, 6 qualitative, 10 quantitative, and qualitative) during COVID-19, eleven (25.0%) participants (1 quantitative, 7 qualitative, 3 quantitative, and quantity) after 100 days, and 14 (31.8%) participants (1 quantitative, 10 qualitative, 3 quantitative and qualitative) after 244 days. Four (9.1%) participants, who were symptom-free after 100 days reported now recently arisen qualitative changes. Serological and T-cell analysis showed no correlation with impairment of taste and smell. In conclusion, qualitative changes can persist for several months and occur as late-onset symptoms months after full recovery from COVID-19-induced quantitative losses in taste and smell.

Verified
Journal Article
Open access
PDF file
Elvira D'IppolitoElvira D'Ippolito
Elvira D'Ippolito
KWKarolin Wagner
Karolin Wagner
DBDirk H Busch
Dirk H Busch
T cell engineering with antigen-specific T cell receptors (TCRs) has allowed the generation of increasingly specific, reliable, and versatile T cell products with near-physiological features. However, a broad applicability of TCR-based therapies in cancer is still limited by the restricted number of TCRs, often also of suboptimal potency, available for clinical use. In addition, targeting of tumor neoantigens with TCR-engineered T cell therapy moves the field towards a highly personalized treatment, as tumor neoantigens derive from somatic mutations and are extremely patient-specific. Therefore, relevant TCRs have to be de novo identified for each patient and within a narrow time window. The naïve repertoire of healthy donors would represent a reliable source due to its huge diverse TCR repertoire, which theoretically entails T cells for any antigen specificity, including tumor neoantigens. As a challenge, antigen-specific naïve T cells are of extremely low frequency and mostly of low functionality, making the identification of highly functional TCRs finding a “needle in a haystack.” In this review, we present the technological advancements achieved in high-throughput mapping of patient-specific neoantigens and corresponding cognate TCRs and how these platforms can be used to interrogate the naïve repertoire for a fast and efficient identification of rare but therapeutically valuable TCRs for personalized adoptive T cell therapy.

12 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EDEmilio Dorigatti
Emilio Dorigatti
FDFelix Drost
Felix Drost
ASAdrian Straub
Adrian Straub
PHPhilipp Hilgendorf
Philipp Hilgendorf
KWKarolin Wagner
Karolin Wagner
BSBenjamin Schubert
Benjamin Schubert
Cancer cells or pathogens can escape recognition by T cell receptors (TCRs) through mutations of immunogenic epitopes. TCR cross-reactivity, i.e., recognition of multiple epitopes with sequence similarities, can be a factor to counteract such mutational escape. However, cross-reactivity of cell-based immunotherapies may also cause severe side effects when self-antigens are targeted. Therefore, the ability to predict the effect of mutations in the epitope sequence on T cell functionality in silico would greatly benefit the safety and effectiveness of newly-developed immunotherapies and vaccines. We here present “Predicting T cell Epitope-specific Activation against Mutant versions” (P-TEAM), a Random Forest-based model which predicts the effect of point mutations of an epitope on T cell functionality. We first trained and tested P-TEAM on a comprehensive dataset of 36 unique murine TCRs in response to systematic single-amino acid mutations of their target epitope (representing 5.472 unique TCR-epitope interactions). The model was able to classify T cell reactivities, corresponding to in vivo recruitment of T cells, and quantitatively predict T cell functionalities for unobserved single-point mutated altered peptide ligands (APLs), or even unseen TCRs, with consistently high performance. Further, we present an active learning framework to guide experimental design for assessing TCR functionality against novel epitopes, minimizing primary data acquisition costs. Finally, we applied P-TEAM to a novel dataset of 7 human TCRs reactive to the tumor neoantigen VPSVWRSSL. We observed a similarly robust performance for these human TCRs as for the murine TCRs recognizing SIINFEKL, thus providing evidence that our approach is applicable to therapeutically relevant TCRs as well as across species. Overall, P-TEAM provides an effective computational tool to study T cell responses against mutated epitopes.